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1114 and 1120. Over one-half million cardiac surgical proceduresare performed in the United States and a largenumber of these procedures require cardiopulmo-nary bypass (CPB) and cardioplegic arrest. How-ever, transient left ventricular (LV) dysfunctioncan occur with reperfusion and separation from
CPB and result in a complex postoperative course. The causes for
this LV pump dysfunction are multifactorial and include intrinsic
defects in myocardial contractile performance and alterations in
hemodynamic loading conditions. Neurohormonal system activa-
tion and subsequent release of bioactive peptides occur during and
after CPB and cardioplegic arrest. One of the more potent bioactive
peptides released into the systemic vasculature under these condi-
tions is endothelin-1 (ET).1-9 Increased synthesis and release of ET
has been implicated to exacerbate LV pump dysfunction in a
number of cardiovascular diseases.8-12 Thus, elevated ET in patients
during and after cardiac surgery may compromise LV function and
contribute to a complex postoperative course.13-17 In the two com-
panion studies by Verma and colleagues18,19 in this issue of the Journal, of Thoracic
and Cardiovascular Surgery, the authors demonstrated that ET can contribute to
myocardial cell injury and microvascular constriction after an episode of controlled
ischemia-reperfusion, which was particularly pronounced in the context of hyper-
glycemia or diabetes. These findings add to the body of knowledge to suggest that
ET contributes to abnormalities in cardiovascular regulation after cardioplegic arrest
and CPB and can further exacerbate these processes in pre-existing disease states
such as diabetes. Comprehensive reviews and texts on the molecular biology,
biosynthesis, and signaling of ET have been published.7-10 However, a brief review
with respect to the biology of ET and the different cellular functions within the
cardiovascular system would be appropriate to place these recent studies into
context with our emerging understanding of the importance of ET in the cardiac
surgical setting.
ET and ET Receptor Systems
The mature 21 amino acid peptide endothelin-1, or ET-1, is synthesized from a 38
amino acid precursor, also known as “big endothelin.” Big ET is then converted to
the biologically active ET-1 by an ET-converting enzyme.7 The diverse physiologic
actions of ET-1 appear to be mediated through two receptor subtypes, the ETA and
ETB receptors. However, the relative affinity of ET-1 for these receptor subtypes is
equivalent. In light of the fact that ET-1 appears to be the most potent species of ET
and has a high and equal affinity for both major receptor subtypes, then these peptide
species are often referred to in generic terms as ET. The production of ET was first
described in endothelial cells, but the synthesis of ET has now been identified to
occur in a number of cell types including smooth muscle cells and cardiac myo-
cytes.18,20-22 Thus, the production and release of ET can occur locally within the
vascular and myocardial compartments, which in turn will regulate a number of
physiologic processes.
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ET causes potent vasoconstriction of several vascular sys-
tems including the myocardial and pulmonary vascular sys-
tems.7-12 Potent constriction of vascular smooth muscle
occurs primarily through binding of ET to the ETA receptor
and, through several intracellular signaling events, increases
calcium availability to the contractile elements. The ETB
receptor contributes to the regulation of vascular smooth
muscle tone in several different ways. First, ETB receptors
located on endothelial cells mediate vasodilation via the
release of nitric oxide and prostacyclins.7-9 Second, this
receptor subtype can also exert vasoconstriction when lo-
cated on the smooth muscle cells.10,12,23 Therefore, the net
contractile effect of ET depends mainly on the relative
density of ETA and ETB receptors on smooth muscle cells
and of ETB receptors on endothelial cells. It has been re-
ported previously that ET can induce a robust and prolonged
vasoconstriction of internal thoracic artery and saphenous
vein segments harvested for use as conduits in coronary
revascularization procedures.5,24,25 Moreover, the vasocon-
strictive effects of ET are more pronounced in arteries with
atherosclerotic disease, and ET amplifies coronary artery
contractions induced by norepinephrine and serotonin.24,25
Coronary atherosclerotic disease and heightened neurohor-
monal system activation coexist in the cardiac surgical
setting and therefore may enhance the vasoconstrictive ef-
fects of ET within the myocardial vasculature. Past studies
have demonstrated that alterations in ET sensitivity can
occur within the systemic vasculature in diabetes.26,27 In the
present report by Verma and colleagues,19 ET mediated a
potent vasoconstrictive effect within the myocardial micro-
vasculature, which was particularly pronounced in diabetic
samples after CPB. These investigators reported diminished
ET-mediated nitric oxide release in the diabetic myocardial
samples. Thus, these new results coupled with past obser-
vations suggest that defects in the ETB receptor system
occur in diabetes, which would result in an exaggerated
vasoconstrictive response to ET.
ET and Cardiac Myocyte Function
Whereas the vasoconstrictive effects of ET are widely rec-
ognized, activation of the ETA receptor has direct effects on
myocyte biology, including contractile protein interactions,
inotropic state, protein expression, and electrophysiology.
Studies from this laboratory and others have demonstrated
abundant myocyte sarcolemmal ET receptors that are pri-
marily of the ETA receptor subtype.21,22,28 Furthermore,
these past studies demonstrated that the LV myocyte has the
capacity to synthesize and release immunoreactive ET and
activate local sarcolemmal ETA and ETB receptors. Thus, in
addition to the systemic effects of ET, local myocyte ET
production and ETA receptor activation may directly influ-
ence LV contractile processes. Recent studies have demon-
strated that persistent activation of these ET receptor path-
ways can directly result in a negative contractile effect in
isolated LV myocytes, myocardial preparations, and in the
intact LV.21,22,33-36
Fundamental intracellular events that have been reported
to occur after ETA receptor activation are the release or
release and mobilization of intracellular calcium (Ca2) and
intracellular pH changes.28-32 Since ETA receptor activation
can cause increased release of intracellular Ca2, then ac-
tivation of this receptor system after cardioplegic arrest and
reperfusion would potentially exacerbate intracellular Ca2
homeostasis and contractile function. An important sar-
colemmal exchange system that directly influences intracel-
lular pH is the Na/H exchanger. Intracellular pH under
normal ambient conditions is maintained relatively alkaline
when compared with the extracellular environment, and this
is achieved through the transport of protons out of the
myocyte. This exchange system has the capacity to correct
an intracellular acid load during periods of ischemia through
an acceleration of H extrusion and intracellular accumu-
lation of Na. This increased intracellular Na can, in turn,
increase the exchange rate of the Na/Ca2 exchanger with
a subsequent accumulation of intracellular Ca2. Several
studies have demonstrated that the Na/Ca2 exchanger
directly contributes to the increased influx and accumulation
of Ca2 during ischemia and reperfusion.37,38 Thus, during
early reperfusion, intracellular Ca2 homeostasis could be
further aggravated by the activation of the Na/H ex-
changer.39,40 It has been demonstrated that activation of the
ETA receptor caused increased activity of the Na/H ex-
changer, intracellular alkalosis, and altered myocyte con-
tractile performance.41,42 Thus, enhanced ETA receptor ac-
tivation may further exacerbate the intracellular ionic
homeostasis that can occur after cardioplegic arrest and
reperfusion. In the companion study by Verma and col-
leagues,18 a human myocardial cell system was established
and maintained under hyperglycemic conditions as well as
after simulated ischemia-reperfusion.18 Several important
findings regarding the ET system were identified from this
study. First, a human myocardial cell culture system syn-
thesized ET under basal conditions and was enhanced after
ischemia-reperfusion. Second, the elaboration of ET with
ischemia-reperfusion activated the ETA receptor and subse-
quently caused cell injury. Third, the ETA receptor–medi-
ated cell injury was further pronounced in myocardial cell
cultures maintained under hyperglycemic conditions. Thus,
an acceleration of ET synthesis within the myocardial com-
partment with ischemia and reperfusion can cause detrimen-
tal effects on myocyte contractile performance and viability.
Increased ET after Cardioplegic Arrest and CPB
A 3- to 6-fold increase in systemic ET levels has been
documented to occur immediately after cardioplegic arrest
and reperfusion.1-6,19 A number of clinical studies have
demonstrated that increased ET levels persist well into the
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postoperative period.1-5 The underlying mechanisms for the
increased perioperative ET levels observed during and after
cardiac surgery are probably multifactorial, including re-
duced ET clearance during CPB as a result of reduced
pulmonary vascular flow, damage to endothelium as a result
of absent pulsatile perfusion, increased myocardial ET pro-
duction and release after reperfusion, increased stress from
surgery, and enhanced ET biosynthesis due to thromboxane
release from activated platelets. Animal studies have dem-
onstrated a causative relationship between increased ET
release and alterations in cardiovascular performance after
cardioplegic arrest and CPB.14-17 Clinical studies have re-
ported that elevated plasma ET levels in the early post-CPB
period can be associated with a more complex postoperative
course.4,5 However, ET is synthesized and released into the
local interstitial space and, therefore, levels of this peptide
that are detected in the systemic circulation likely reflect
spill-over from local tissue compartments.6,18,20-22 With the
use of microdialysis techniques, ET levels within the myo-
cardial interstitium can be over 10-fold higher than systemic
levels, and a rapid release of ET can occur within the
myocardial compartment with cardioplegic arrest and reper-
fusion.6
The physiologic consequences of increased local myo-
cardial ET production in the early post–cardiac surgical
setting include vasoconstriction of the native coronary vas-
culature and newly placed coronary conduits that will ham-
per blood flow delivery to the vulnerable myocardium. In
addition, increased ET exposure of myocytes immediately
after cardioplegic arrest can exacerbate contractile function
and inotropic responsiveness.14 Specifically, increased ET
release and activation of myocyte ET receptors likely inter-
fere in -adrenergic–mediated inotropic response in this
critical postoperative period. These past observations, as
well as the reports by Verma and colleagues,18,19 suggest
that ET may directly contribute to a number of pathophys-
iologic processes that can occur after cardioplegic arrest and
CPB.
ET Receptor Antagonists and Potential in Cardiac
Surgery
Potent and specific ETA receptor antagonists, as well as
combined ETA/ETB receptor antagonists, have been de-
scribed.8-12 These new nonpeptide ET receptor antagonists
are constructs with significant bioavailability, prolonged
half-life, and high specificity. ET receptor antagonists have
been successfully used in patients with pulmonary hyper-
tension and heart failure.10-12 These ET receptor antagonists
have been successfully used in several animal models of
cardioplegic arrest and CPB.13,15-17 The ET receptor antag-
onist with the greatest clinical profile to date is the nonse-
lective antagonist bosentan.12,43,44 Specifically, the immedi-
ate administration of bosentan in patients with heart failure
has provided favorable effects on systemic hemodynamics
and pulmonary hypertension.12,44
A clear change in the patient demographics for cardiac
surgery such as coronary revascularization is ongoing, with
the patients being older, having pre-existing abnormalities
in LV structure and function, and having an increasing
incidence of concomitant disease processes such as diabe-
tes. The well-constructed series of in vitro studies per-
formed by the Toronto cardiac surgery group demonstrated
that the elaboration of ET after ischemia and reperfusion or
after cardioplegic arrest can detrimentally affect a number
of cardiovascular processes, particularly in the context of
diabetes.18,19 Moreover, these investigators clearly demon-
strated that ET receptor blockade could abrogate the dele-
terious effects of ET. An intravenous formulation of an ET
antagonist has been developed and acute infusions of this
mixed ET antagonist have been safely deployed in patients
with severe heart failure.44 Although the effects of ET on
myocardial function have received significant attention in
heart failure, the potential deleterious effects of increased
ET release and/or production within the myocardium after
cardioplegic arrest and reperfusion and the underlying
mechanisms for these effects are beginning to emerge. The
time for well-designed, hypothesis-driven, preclinical and
clinical studies regarding the mechanistic role of ET to
contribute to postoperative recovery with respect to LV
function, systemic hemodynamics, and coronary graft via-
bility is now upon us.
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